🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "huge turning point" in the battle against drug-resistant strains of the bacteria, according to researchers.

An International Public Health Issue

Cases of gonorrhoea are increasing worldwide, with data suggesting more than 82 million new cases each year. Particularly high rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary development in the face of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted therapeutic options currently available.”

Public health authorities are increasingly worried about the surge in drug-resistant strains. The World Health Organization has designated it as a "high-priority threat". Recent surveillance revealed that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Secure Authorization

Zoliflodacin, marketed under the name a brand name, was approved by the US Food and Drug Administration in mid-December for use against gonorrhoea. This disease can lead to significant complications, including infertility. Researchers anticipate that targeted use of this new drug will help delay the development of resistance.

Another new antibiotic, originating from the drugmaker GSK, also received approval in the same week. This medication, which is also used to treat urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment was the result of a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to develop it.

“This authorization represents a significant shift in the management of multidrug-resistant gonorrhoea, which previously has been staying ahead of medical innovation.”

Clinical Trial Results and Worldwide Availability

As per findings released by a prominent scientific publication, the new drug cured the vast majority of cases of the STI. This puts it on an similar efficacy with the current standard treatment, which involves two antibiotics. The trial enrolled hundreds of patients from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the rights to license and sell the drug in many regions with limited resources.

Doctors treating patients have expressed optimism. Access to a single-dose, oral treatment of this kind is hailed as a "critical tool" for gonorrhoea control. This is viewed as crucial to lessen the impact of the disease for individuals and to stop the proliferation of extremely resistant gonorrhoea globally.